BlueOnion and Morningstar Sustainalytics Collaborate to Expand Sustainable Investment and Due Diligence Coverage
With the surge in ESG assets and heightened regulatory scrutiny—such as the recent circular issued by the Hong Kong Monetary Authority (HKMA) on the Sale and Distribution of Sustainable Investment Products, the synergistic interplay between BlueOnion's analytics and Morningstar Sustainalytics' data will enhance the financial sector's efforts in meeting compliance requirements in a transparent and fuss free manner.
Together, the BlueOnion SFDR product and Morningstar Sustainalytics' data expand coverage to 300,000 mutual funds, ETFs, and 93,000 bond funds, offering broader insights for sustainable investing. The platform standardizes sustainability product measurement, aligns with the EU SFDR, and empowers organizations to analyze ESG performance, assess carbon emissions, avoid controversies, and address climate change—all while meeting regulatory and investor expectations with transparency and confidence.
'Proper due diligence is essential for banks to meet regulatory compliance and for asset managers to build portfolios aligned with global sustainability standards. This process depends on robust data, analytics, and clear visualization. BlueOnion's advanced analytics and visualization capabilities, together with our robust data, bridges a gap in the fixed income asset class and the small to mid-cap coverage. As a turnkey solution, it helps our banking and fund clients save time and costs,' said Nick Cheung, Managing Director of Enterprise Products, Greater China, Morningstar.
This collaboration allows clients to seamlessly integrate Morningstar Sustainalytics' data with BlueOnion's existing data and analytics solution on sustainability, offering clients an intuitive solution to tackle challenges in regulatory compliance and sustainability-focused investment strategies.
'We are excited to collaborate with Morningstar to deliver a transformative, turnkey solution that empowers banks and asset managers on their sustainability journey. By combining Morningstar's unparalleled global fund data and analytics expertise with BlueOnion's innovative platform, we provide deeper insights into funds pursuing sustainability integration, transition, and impact through EU taxonomy-related activities. Together, we are elevating industry standards in ESG research, data quality, and transparency, driving meaningful impact and innovation,' said Elsa Pau, Group CEO of BlueOnion.
This collaboration exemplifies BlueOnion and Morningstar Sustainalytics's commitment to supporting financial institutions in combating greenwashing, achieving compliance, and advancing the global ESG agenda. Together, they enable clients to uncover actionable insights and drive meaningful progress in sustainable investing.
Hashtag: #BlueOnion
The issuer is solely responsible for the content of this announcement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Barnama
4 days ago
- Barnama
Morningstar Launches New Digital Destination to Empower Asian Investors
SINGAPORE, June 30 (Bernama) -- Morningstar, Inc. (Nasdaq: MORN), a leading provider of independent investment insights, today announced the launch of its new Asia digital investment research hub, designed to empower investors with localized investment research, data, and insights. The new digital destination is free and offers region-specific investment and market content, data, and tools tailored to the needs of Asian investors. Part of a suite of 12 new digital experiences created for distinct markets around the world, today's launch reflects Morningstar's commitment to serving local investors, backed by the strength of the company's global independent research and long-term perspective. The new digital experiences replace legacy ones across markets.
The Star
09-06-2025
- The Star
Crypto funds' assets hit record high as investors hedge and diversify
Representations of cryptocurrency bitcoin are seen in this illustration picture created in Paris, France, March 9, 2024. REUTERS/Benoit Tessier/Illustration (Reuters) -Assets held in crypto funds hit a record high in May as easing trade tensions lifted risk appetite and some investors used the digital currencies to hedge against market volatility and diversify from their U.S. holdings. Morningstar data on 294 crypto funds shows they attracted $7.05 billion in net inflows last month, the highest since December, bringing total assets under management to a record $167 billion. Nicolas Lin, CEO of fintech firm Aether Holdings, said bitcoin "is starting to come into its own again", not just as a high-volatility asset, but as something that more investors are using to hedge their exposure. Bitcoin has gained more than 15% over the past three months, outperforming a 3.6% rise in the MSCI World Index and a 13.3% gain for gold. Nic Puckri, analyst and founder of Coin Bureau, said one of the main drivers of bitcoin's rise is a loss of faith in the U.S. investment story. "The greenback is projected to keep plummeting, bond yields are rising, there's uncertainty about the equity markets. But bitcoin seems to be holding strong." Bitcoin has been buoyed by institutional inflows over the past year following the approval of spot bitcoin and ether ETFs in the United States. In contrast to the crypto funds, Lipper data showed a net $5.9 billion flowed out of global equity funds in May, while gold funds posted their first outflow in 15 months, of $678 million, pointing to a broader shift in portfolio diversification. "I think flows will stay strong, but probably more steady than the rush we saw after the ETFs launched," said Aether Holdings' Lin. "That initial wave was a bit of a release valve. What's happening now is more important, it's the start of crypto becoming a permanent fixture in diversified portfolios." According to Coinshares data, bitcoin funds attracted a net $5.5 billion and ether funds a net $890 million in May.
Malaysian Reserve
27-05-2025
- Malaysian Reserve
Phanes Therapeutics announces first patient dosed in clinical study of mavrostobart (PT199) in combination with chemotherapy
SAN DIEGO, May 27, 2025 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the first patient has been dosed in the clinical study of mavrostobart (PT199) in combination with chemotherapy. Mavrostobart is an anti-CD73 monoclonal antibody with a differentiated mechanism of action and is designed to counter the adenosine-mediated immunosuppressive tumor microenvironment (TME). Mavrostobart fully inhibits the enzyme activities of both soluble and membrane-bound CD73, unlike several other anti-CD73 antibodies which exhibit incomplete inhibition. Moreover, at higher concentrations, no loss of inhibition or 'hook effect' is observed with mavrostobart. Hence, mavrostobart addresses the limitations of current CD73 inhibitors and is expected to increase antitumor immune activation, and potentially offer a new treatment option for cancer patients. The multi-center Phase I/II clinical trial of mavrostobart (NCT05431270), known as the MORNINGSTAR study, is currently evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of mavrostobart alone and in combination with a PD-1 Inhibitor or chemotherapy. A Phase I clinical trial of mavrostobart is also ongoing in China (CTR20242381). ABOUT PHANES THERAPEUTICS Phanes Therapeutics, Inc. is a clinical stage biotech company focused on innovative drug discovery and development in oncology. Currently, it is conducting three Phase I/II clinical trials, including the MORNINGSTAR study with its best-in-class monoclonal antibody (mAb) program, mavrostobart (PT199), the TWINPEAK study with spevatamig (PT886) and the SKYBRIDGE study with peluntamig (PT217). Both spevatamig and peluntamig are first-in-class bispecific antibodies and have been granted orphan drug designations as well as Fast Track designations by the FDA. The company has built a strong pipeline by leveraging its proprietary technology platforms: PACbody®, SPECpair® and ATACCbody® to develop novel biologics that address high unmet medical needs in cancer. For more information about Phanes Therapeutics, please visit For business development or media inquiries, please contact bd@ or media@ respectively.
